Vorsetuzumab mafodotin Drug Asset Due Diligence Report 2026

This Vorsetuzumab mafodotin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Discontinued

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Vorsetuzumab mafodotin can convert its Antibody drug conjugate (ADC) profile and CD70 x Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Vorsetuzumab mafodotin (query alias: mafodotin)
Modality / target	Antibody drug conjugate (ADC); CD70 x Tubulin; CD70 inhibitors, Tubulin inhibitors
Highest global status	Discontinued
Originator	Seagen, Inc.
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT01015911	Phase 1	Completed	58	Incidence of adverse events and laboratory abnormalities
NCT01677390	Phase 1	Terminated	4	Incidence of adverse events and laboratory abnormalities

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

Phase 1; n=58; evaluation: not stated. Reported fields: Adverse Event: idiopathic thrombocytopenic purpura = idiopathic thrombocytopenic purpura in 2 NHL patients treated weekly

SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma.

Phase 1; n=58; evaluation: not stated. Reported fields: AEs ≥30% of RCC pts = 52 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Vorsetuzumab mafodotin addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 12 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD70 x Tubulin records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-05-14	Allogene Therapeutics ends China cell therapy deal with Overland	Phase 1	Financial terms not disclosed
2024-12-18	Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform	Preclinical	Financial terms not disclosed
2024-04-03	18亿美元现金ADC交易，Genmab收购普方生物	IND Application	US$1,800.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of treating cancer with a combination of a nonfucosylated Anti-CD70 antibody and a CD47 antagonist”. The milestone feed surfaced a patent-application signal described as “Methods of treating cancer with combination of non-fucosylated anti-CD70 antibody and CD47 antagonist”. The milestone feed surfaced a patent-application signal described as “Methods of treating cancer with nonfucosylated Anti-CD70 antibodies”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

CLDN18.2 assay, cutoff, and intratumoral heterogeneity
Payload-related toxicity and dose intensity
Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION